GSK delivers strong Q3 performance with underlying sales growth of 6% and reported sales growth of 3%
Full details of GSK's results for the third quarter of 2011 can be found in the Investors section of GSK.com.
Issued: Wednesday 26 October 2011, London, UK
- EPS 28.5p +1% before major restructuring*
- Dividend +6% to 17p
- 2011 share buyback expectations increased to up to £2.3 billion
Full details of GSK's results for the third quarter of 2011 can be found in the Investors section of GSK.com.
GlaxoSmithKline enquiries: |
||
|
UK Media enquiries: |
David Mawdsley |
(020) 8047 5502 |
|
Stephen Rea |
(020) 8047 5502 |
|
|
Sarah Spencer |
(020) 8047 5502 |
|
|
Janet Morgan |
(020) 8047 5502 |
|
|
David Daley |
(020) 8047 5502 |
|
|
US Media enquiries: |
Nancy Pekarek |
(919) 483 2839 |
|
Mary Anne Rhyne |
(919) 483 2839 |
|
|
Kevin Colgan |
(919) 483 2839 |
|
|
Jennifer Armstrong |
(919) 483 2839 |
|
|
European Analyst/Investor enquiries: |
Sally Ferguson |
(020) 8047 5543 |
|
Gary Davies |
(020) 8047 5503 |
|
|
Ziba Shamsi |
(020) 8047 3289 |
|
|
US Analyst/ Investor enquiries: |
Tom Curry |
(215) 751 5419 |
|
Jeff McLaughlin |
(215) 751 7002 |
GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2010.
